soligenix.com (SNGX) - Koefisien utang jangka dawa marang modal

Soligenix, Inc. (SNGX) maintains resilience through a mix of government biodefense contracts and commercial products. The long-term debt-to-equity history visualizes this balance, where 0.03 represents the latest level. The company's technological leadership is based on synthetic peptides for treating rare pathologies, while stable management effectively secures grants to advance clinical trials.

Soligenix, Inc. (SNGX) is developing a highly specialized portfolio of orphan drugs with strong patent protection. The long-term debt-to-equity ratio relates liabilities with a maturity of more than one year to the issuer's own equity. This metric determines the extent of the balance sheet structure's dependence on debt financing and the associated default risks. The trend in the long-term debt-to-equity ratio allows for the differentiation of secondary offerings from scheduled loan repayments. A low debt load confirms the financial stability of the company within the rare disease niche.